Connect with us

Hi, what are you looking for?

Economy

Wolbachia bacteria ‘dramatically reduces’ dengue — study

By Patricia B. Mirasol

DENGUE FEVER cases have been cut by 77% in a trial that infected disease-spreading mosquitoes with a bacteria called Wolbachia, according to the results of a randomized controlled trial published this June in the New England Journal of Medicine.

The study has significant implications for 40% of the world’s population at risk of dengue, according to the World Mosquito Program (WMP) initiated by Monash University, Australia.

Wolbachia is a naturally occurring bacteria that exists in around 50% of all insects, but not the Aedes aegypti mosquito until it was introduced in the laboratory by WMP researchers. Wolbachia restricts the amount of dengue that disseminates from the mosquito midgut into the mosquito’s saliva.

“At the cellular level, replication of the viral genome is inhibited when the virus infects cells that are also occupied by Wolbachia,” Katie Anders, WMP’s lead researcher and director of impact assessment, told BusinessWorld in an e-mail interview. “This is likely due to competition between Wolbachia and viruses for resources such as energy and nutrients.”

DRAMATIC REDUCTION
In Yogyakarta City, Indonesia, and surrounding areas where the infected mosquitoes were released, the number of cases of dengue decreased significantly compared with parts of the city where they were not, according to the three-year Applying Wolbachia to Eliminate Dengue trial, conducted by WMP in collaboration with Indonesia’s Tahija Foundation and Gadjah Mada University.

Once Wolbachia-carrying mosquitoes are released, they breed with wild mosquitoes. Over time, the percentage of mosquitoes carrying Wolbachia grows until it remains high without the need for further releases.

“It takes between three to six months of mosquito releases undertaken every one to two weeks for Wolbachia to become established in the local mosquito population,” said Ms. Anders. “We then see reduced dengue in the years that follow.”

This self-sustaining method is said to offer a safe, effective, and long-term solution to reducing the burden of the disease.

WMP director Scott O’Neill said in a press statement: “This is the result we’ve been waiting for — evidence that our Wolbachia method is safe, sustainable, and dramatically reduces incidence of dengue. It gives us great confidence in the positive impact this method will have worldwide when provided to communities at risk of these mosquito-transmitted diseases.”

The “public health value of Wolbachia against dengue” was recognized by the World Health Organization’s (WHO) Vector Control Advisory Group in a December 2020 virtual meeting.

Climate change amplified the distribution of Aedes aegypti, the mosquito species that transmit the dengue virus, according to WHO. Other factors including rapid unplanned urbanization, increased humidity, devolved vector control services, and movement of people and goods have also facilitated the spread of the disease.

Dengue is common in more than 100 countries around the world, including the Philippines. And a person can be infected with a dengue virus as many as four times in his or her lifetime.

In August 2020, the Philippines’ Department of Health (DoH) reported that its W.I.L.D. (or water-borne infectious diseases, influenza, and leptospirosis, including dengue) initiative resulted in a drop of dengue cases (59,675 in 2020 from 430,282 in 2019) and mortalities (231 in 2020 from 1,612 in 2019). Among the activities implemented by the DoH is the Wolbachia Project within Bicol’s Center for Health Development as part of a non-invasive way to control the local dengue-carrying mosquito population.

Because the Wolbachia project in Bicol is ongoing, WMP declined to comment until after the results of the study are available.

WOLBACHIA WORLDWIDE
WMP aims partner with national and local governments, corporate citizenship programs, charitable organizations, and non-governmental organizations to expand Wolbachia protection worldwide. To date, the WMP has supported releases in 11 countries in Asia, Australia, Latin America, and the Pacific, with an estimated 6.8 million people benefiting from Wolbachia coverage.

The cost of deployment is currently less than $10 per person, said Ms. Anders, with the organization working towards reducing it to $1 per person. “In high-density urban areas, Wolbachia is expected to be cost-saving over 10 years, returning 2–3 dollars in economic benefits for every dollar invested through averted healthcare costs and lost wages,” she said.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Investing

The national pig herd has lost-one tenth of all sows over the last six months, farmers’ associations have revealed, after breeders were forced into...

Investing

EasyJet plunged £213 million into the red in the Christmas quarter and is still burning through £150 million in cash each month, putting its...

Investing

A new range of healthy yet indulgent cookies will launch in Booths this month for just £1 per pack with the UK-born snacks by...

Investing

Payments firm Checkout.com has raised $1bn (£730m), giving it a $40bn (£29bn) valuation and crowning it the UK’s most valuable private fintech. The London-headquartered...

Investing

Sylvera, a UK-based startup that provides ratings for carbon offsets, has raised $32.6m (£24.1m) in a Series A funding round to accelerate and expand...

Investing

UK-based fintech Everything has raised €2m (£1.67m) to reinvent a decades-old financial product: premium bonds. The raise was led by a group of angel...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.